Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

ABSTRACT: Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

PROVIDER: PRJNA985573 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24968700_1.fastq.gz	Fastqsanger.gz
	SRR24968700_2.fastq.gz	Fastqsanger.gz
	SRR24968800_1.fastq.gz	Fastqsanger.gz
	SRR24968800_2.fastq.gz	Fastqsanger.gz
	SRR24968701_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 440

Similar Datasets

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

Project description:Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

| PRJNA1158224 | ENA

Evaluation of breast cancer PDX tumor heterogeneity

Project description:Evaluation of breast cancer PDX tumor heterogeneity

| PRJNA984700 | ENA

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

Project description:Breast cancer is the most commonly diagnosed cancer among women. PDXs (patient-derived xenografts) are similar to cancer cell lines but differ in that they are maintained in a physiological setting as soon as they are isolated from the patient and for subsequent passages. These models are valuable for preclinical trials because PDX models have been shown to closely match their patient counterparts, both in genomic profile and response to treatment. One challenge to treatment development is tumor heterogeneity. In this study, we profiled ER+ and triple negative breast cancer PDX models using single-cell RNA-sequencing. This data may help identify populations of cells which are susceptible to certain treatments in order to improve clinical outcomes for breast cancer patients.

2023-07-18 | GSE235168 | GEO

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

2024-09-30 | GSE276609 | GEO

scRNA-seq of lung CD140a+ mesenchymal cells (fibroblasts) from CD140a-EGFP reporter mice

Project description:To investigate the heterogeneity of lung CD140a+ mesenchymal cells (fibroblasts) and identify the specific lung fibroblast subset, we purified CD140a+ lung cells using CD140a-EGFP reporter mice for a higher-resolution scRNA-seq.

2022-07-19 | E-MTAB-11875 | biostudies-arrayexpress

Characterizing the Chemoresistant Ovarian Cancer Population using the Heterogeneous PDX

Project description:The patient-derived xenograft (PDX) model retains the heterogeneity of patient tumors, allowing a means to not only examine efficacy of a therapy across a population, but also study crucial aspects of cancer biology in response to treatment. Herein we describe the development and characterization of an ovarian-PDX model in order to study the development of chemoresistance. We demonstrate that PDX tumors are not simply composed of tumor-initiating cells, but recapitulate the original tumor’s heterogeneity, oncogene expression profiles, and clinical response to chemotherapy. Combined carboplatin/paclitaxel treatment of PDX tumors enriches the cancer stem cell populations, but persistent tumors are not entirely composed of these populations. RNA-Seq analysis of treated PDX tumors compared to untreated tumors demonstrates a consistently contrasting genetic profile after therapy, suggesting similar, but few, pathways are mediating chemoresistance. The pathways most significantly altered included Protein Kinase A signaling, GNRH signaling, and sphingosine-1-phosphate signaling. Pathways and genes identified by this methodology represent novel approaches to targeting the chemoresistant population in ovarian cancer 6 pairs of Patient-Derived Xenografts (PDX) were ananlyzed using RNA-seq for a total of 12 samples. Each pair consists of a treated and untreated PDX of ovarian cancer. Treated Ovarian cancer PDXs were treated with 4 weeks of a combination of carboplatin and taxol. RNA was isolated and converted to cDNA. RNA-seq was conductred on the Illumina HiSeq 2000 with 50 bp paired end sequencing

2015-06-17 | E-GEOD-58586 | biostudies-arrayexpress

Characterization of a luminal breast cancer patient-derived xenograft (PDX) via single-cell RNA-sequencing (scRNA-seq)

Project description:Luminal breast cancers are characterized by estrogen-regulated gene profiles. We performed scRNA-seq on a luminal breast cancer PDX named GS1 to profile the gene expression of the cells constituting GS1 tumor and to investigate the effect of estrogen on the individual populations.

2024-02-02 | GSE213733 | GEO

Evaluation of tofacitinib in cutaneous sarcoidosis [scRNA-seq]

Project description:Evaluation of tofacitinib in cutaneous sarcoidosis [scRNA-seq]

| PRJNA715583 | ENA

An Improved Bacterial Single-cell RNA-seq Reveals Biofilm Heterogeneity [scRNA-seq]

Project description:In contrast to mammalian cells, bacterial cells lack mRNA polyadenylated tails, presenting a hurdle in isolating mRNA amidst the prevalent rRNA during single-cell RNA-seq. This study introduces a novel method, Ribosomal RNA-derived cDNA Depletion (RiboD), seamlessly integrated into the PETRI-seq technique, yielding RiboD-PETRI. This innovative approach offers a cost-effective, equipment-free, and high-throughput solution for bacterial single-cell RNA sequencing (scRNA-seq). By efficiently eliminating rRNA reads and substantially enhancing mRNA detection rates (up to 92%), our method enables precise exploration of bacterial population heterogeneity. Applying RiboD-PETRI to investigate biofilm heterogeneity, distinctive subpopulations marked by unique genes within biofilms were successfully identified. Notably, PdeI, a marker for the cell-surface attachment subpopulation, was observed to elevate cyclic diguanylate (c-di-GMP) levels, promoting persister cell formation. Thus, we address a persistent challenge in bacterial single-cell RNA-seq regarding rRNA abundance, exemplifying the utility of this method in exploring biofilm heterogeneity. Our method effectively tackles a long-standing issue in bacterial scRNA-seq: the overwhelming abundance of rRNA. This advancement significantly enhances our ability to investigate the intricate heterogeneity within biofilms at unprecedented resolution.

2024-12-10 | GSE260457 | GEO

Prediction of outcomes and response to treatments with an ultrasensitive method for assessing intratumor epigenetic heterogeneity in colorectal cancer

Project description:Primary outcome(s): The detection rates of epigenetic heterogeneity in primary tumor and plasma from colorectal cancer patients with Methylation-sensitive high resolution melt(MS-HRM).

| 2636460 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data